Oncolytics Biotech Stock Climbs on FDA Meeting and Trial Expansion

The proposed expansion involves adding a second phase, designated as Part B, to the REO-033 clinical trial. Leadership at Oncolytics aims to leverage this structure to facilitate both accelerated and traditional approval pathways within a single study. This strategic pivot comes as the company reports steady momentum in its research infrastructure.

Operational progress remains on schedule, with approximately half of the planned clinical centers slated for activation throughout July. Oncolytics expects to bring additional sites online by the end of August, supported by a recruitment pipeline that has already pre-identified more than 20 patients across participating medical centers.